Aquestive Accounts Payable from 2010 to 2024

AQST Stock  USD 5.09  0.07  1.36%   
Aquestive Therapeutics Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable is likely to outpace its year average in 2024. Accounts Payable is the amount Aquestive Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Aquestive Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2007-03-31
Previous Quarter
5.7 M
Current Value
7.6 M
Quarterly Volatility
4.9 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aquestive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aquestive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 9.5 M, Selling General Administrative of 43.5 M or Total Revenue of 48.2 M, as well as many indicators such as Price To Sales Ratio of 3.76, Dividend Yield of 0.0 or Days Sales Outstanding of 47.57. Aquestive financial statements analysis is a perfect complement when working with Aquestive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aquestive Therapeutics Correlation against competitors.
For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

Latest Aquestive Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Aquestive Therapeutics over the last few years. An accounting item on the balance sheet that represents Aquestive Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Aquestive Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Aquestive Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aquestive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Aquestive Accounts Payable Regression Statistics

Arithmetic Mean8,470,966
Geometric Mean7,469,476
Coefficient Of Variation48.53
Mean Deviation2,635,826
Median7,089,000
Standard Deviation4,110,647
Sample Variance16.9T
Range19.2M
R-Value0.47
Mean Square Error14.2T
R-Squared0.22
Significance0.08
Slope430,723
Total Sum of Squares236.6T

Aquestive Accounts Payable History

20249.4 M
20238.9 M
20229.9 M
20218.3 M
20207.1 M
201912.3 M
201820.4 M

About Aquestive Therapeutics Financial Statements

Aquestive Therapeutics shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Aquestive Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aquestive Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aquestive Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable8.9 M9.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.